Completed PHASE1 INTERVENTIONAL 2-arm NCT03659435

Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (9.5mg/24h)

Open, Randomized, 2-period, 2-sequence, Cross-over Relative Bioavailability Study to Investigate the Pharmacokinetics and to Assess the Bioequivalence of a Rivastigmine Test Patch Formulation 9.5 mg/24 h (Twice Weekly Patch) Compared to the Reference Exelon® 9.5 mg/24 h (Once Daily Patch) Applied for 11 Days

Sponsor: SocraMetrics GmbH

Conditions Bioequivalence

Interventions Exelon® 9.5 mg/24 h RID-TDS 9.5 mg/24 h

Updated 5 times since 2018 Last updated: Sep 18, 2019 Started: Aug 22, 2018 Primary completion: Nov 28, 2018 Completion: Nov 28, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03659435, this PHASE1 trial focuses on Bioequivalence and remains completed. Sponsored by SocraMetrics GmbH, it has been updated 5 times since 2018, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Oct 2019 — Jan 2021 [monthly]

Completed PHASE1

Status: Recruiting → Completed
Oct 2018 — Oct 2019 [monthly]

Recruiting PHASE1

First recorded

Aug 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

SocraMetrics GmbH
SocraTec R&D GmbH

Data source: SocraTec R&D GmbH

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Erfurt, Germany